ketorolac tromethamine has been researched along with Retinal Neovascularization in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, A; Bingaman, DP; Campochiaro, PA; Melia, MB; Mori, K; Nambu, H; Oshima, Y; Saishin, Y; Takahashi, K; Yamamoto, S | 1 |
1 other study(ies) available for ketorolac tromethamine and Retinal Neovascularization
| Article | Year |
|---|---|
Topical nepafenac inhibits ocular neovascularization.
Topics: Administration, Topical; Animals; Benzeneacetamides; Choroidal Neovascularization; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Isoenzymes; Ketorolac Tromethamine; Lymphokines; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ophthalmic Solutions; Phenylacetates; Prodrugs; Prostaglandin-Endoperoxide Synthases; Retinal Neovascularization; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |